Rapid in vivo Screening of Gene Delivery, Anticancer Efficacy and Cell Trafficking Using Bioluminescence Imaging

Rapid, precise and non-invasive in vivo assessment of gene therapy and antitumor efficacy in deep tissue tumor models is feasible through the use of luciferase reporters and bioluminescence imaging (BLI). BLI is well-suited for quantifying tumor growth and treatment pharmacodynamics in orthotopic, hematologic and metastasis models of cancer.

Since luciferase reporters can be relatively easily and effectively incorporated into these biologic platforms, BLI has become the preferred platform for screening prior to moving into early clinical studies. Furthermore, luciferase is used to test gene reporter platforms using translational gene reporters, such as HSV-TK.

In this webinar, Dr. McConville will provide an overview of state-of-the art-applications that utilize luciferase reporters and bioluminescent imaging, including gene delivery and oncolytic virus examples. Dr. Timberlake will showcase bioluminescence imaging based screening approaches to interrogate CAR-T cell efficacy, tracking and activation.

This webinar reviews:

• How luciferase is used as a sensitive gene reporter for the detection of cells and biological therapies.  
• How to perform efficient and quantitative in vivo screening of:
  • Gene delivery
  • Cell tracking, including CAR-T cells
  • Efficacy in deep tissue tumor models